France Biotech reviews state of the market
The global credit crisis has led to a "freeze" in investment decision-making for the biotechnology industry, with falls of 79% and 62%, respectively, in Europe and the USA, according to France Biotech, the French trade group. Launching its international review of the biotechnology industry, France Biotech said that, despite the current bad outlook, "growth and innovation in the products and services portfolio of the biotechnology enterprises in France are indeed there to be seen."
The launch in April 2008 of the Next Biotech market index by Euronext, the French trade group argues, makes the biotechnology sector more attractive by making its performance easier to visualize.
The France Biotech report also provided an overview of the biotechnology pipeline, which in France sees 73 candidates in preclinical and 98 in clinical trial phases. This compares with 57 small-molecule drugs in Phases I to III in France.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze